Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Premier Fund Managers Ltd

Premier Fund Managers Ltd grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 46.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,710 shares of the biopharmaceutical company’s stock after purchasing an additional 5,000 shares during the quarter. Premier Fund Managers Ltd’s holdings in Gilead Sciences were worth $1,445,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Orion Portfolio Solutions LLC grew its position in Gilead Sciences by 3.7% in the fourth quarter. Orion Portfolio Solutions LLC now owns 90,026 shares of the biopharmaceutical company’s stock worth $8,316,000 after acquiring an additional 3,224 shares in the last quarter. New Age Alpha Advisors LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth $10,778,000. Kiltearn Partners LLP increased its holdings in shares of Gilead Sciences by 107.9% in the fourth quarter. Kiltearn Partners LLP now owns 150,900 shares of the biopharmaceutical company’s stock worth $13,939,000 after acquiring an additional 78,300 shares in the last quarter. Norges Bank acquired a new stake in Gilead Sciences in the 4th quarter valued at approximately $1,789,254,000. Finally, Caisse Des Depots ET Consignations acquired a new position in Gilead Sciences during the fourth quarter worth $7,821,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of GILD stock opened at $111.16 on Friday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The stock has a 50 day moving average price of $105.08 and a 200 day moving average price of $94.58. The firm has a market capitalization of $138.43 billion, a P/E ratio of 300.43, a P/E/G ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a $0.79 dividend. The ex-dividend date is Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Analysts Set New Price Targets

GILD has been the subject of several research analyst reports. Oppenheimer boosted their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday, March 4th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Bank of America lifted their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Piper Sandler boosted their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Finally, Morgan Stanley upped their price objective on Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research report on Tuesday, March 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $105.12.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This represents a 1.89 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 302,785 shares of company stock valued at $30,503,250 over the last 90 days. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.